Systemic AAV-mediated Gene Therapy Prevents the Multi-organ Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion
Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme in ethanol metabolism, processing toxic aldehyde to nontoxic acetate. ALDH2 deficiency affects 8% of the world population and 35-45% of the East Asians. The ALDH2*2 allele common genetic variant has a glutamic acid-to-lysine substitution at position 487 (E487K), which reduces the oxidizing ability of the enzyme resulting in systemic accumulation of acetaldehyde with ethanol ingestion. ALDH2*2 heterozygotes have a 7 to 12-fold increased risk for esophageal cancer, a risk increased by drinking alcohol and smoking. In ALDH2 deficiency mouse models, chronic ethanol consumption induces DNA damage and adduct accumulation in the esophagus, precursors of cancer. We hypothesized that a one-time administration of an adeno-associated virus (AAV) serotype rh.10 gene transfer vector expressing the human ALDH2 cDNA (AAVrh.10hALDH2) would persistently correct ALDH2 deficiency, prevent systemic accumulation of acetaldehyde, and reduce esophageal DNA damage and adducts accumulation from chronic ethanol ingestion. To assess this hypothesis, AAVrh.10hALDH2 (1011 genome copies) was administered intravenously to 6-10 wk old ALDH2 knockout homozygous (ALDH2-/-) and knockin homozygous (ALDH2E487K+/+) male mice (n=10 per group). Four wk after vector administration, mice were given drinking water with 10-15% ethanol for 12 wk. Systemic serum acetaldehyde was quantified by liquid chromatography/mass spectrometry (LC/MS). Esophageal DNA damage was evaluated by gamma-H2A histone X (γH2AX) immunohistochemistry, and DNA adducts by quantifying N2-ethyl-deoxyguanosine (N2-et-dG) by LC-MS/MS. Compared to non-ethanol drinking littermates, untreated ALDH2-/- and ALDH2E487K+/+ mice had decreased body weight and hemoglobin levels, poor performance in locomotor activity tests, elevated serum acetaldehyde levels, increased esophageal γH2AX positive cells, and increased esophageal N2-et-dG adducts (all p<0.05). Strikingly, AAVrh.10hALDH2-treated ALDH2-/- and ALDH2E487K+/+ chronic ethanol-ingesting mice had correction of all of these abnormalities (all p<0.05). AAVrh.10hALDH2 should be considered as a preventative therapy for the increased risk for esophageal cancer associated with ALDH2 deficiency with chronic alcohol exposure.